Share
Journal Information
Issue
Vol. 18. Issue 3.Pages 409-536 (May - June 2019)
Editorial
Viewpoints
Antioxidants benefits in hepatitis C infection in the new DAAs era
Sonia A. Lozano-Sepúlveda, Ana R. Rincón-Sanchez, Ana M. Rivas-Estilla
Ann Hepatol. 2019;18:410-5
Open access
Concise reviews
Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)
Sebastião M.B. Duarte, Jose Tadeu Stefano, Claudia P. Oliveira
Ann Hepatol. 2019;18:416-21
Open access
Original article
The basis of liver regeneration: A systems biology approach
Mamatha Bhat, Elisa Pasini, Cristina Baciu, Marc Angeli, Atul Humar, Sonya Macparland, Jordan Feld, Ian McGilvray
Ann Hepatol. 2019;18:422-8
Open access
Impact of sustained viral response in the evolution of minimal hepatic encephalopathy: A prospective pilot study
Marta Hernández-Conde, Carlos Fernández-Carrillo, Elba Llop, Christie Perelló, Marta López-Gómez, José L. Martínez-Porras, Natalia Fernández-Puga, José L. Calleja
Ann Hepatol. 2019;18:429-33
Open access
Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study
Raffaella Lionetti, Paola Piccolo, Ilaria Lenci, Massimo Siciliano, Ubaldo Visco-Comandini, Adriano De Santis, Maurizio Pompili, Martina Milana, ... Gianpiero D’Offizi
Ann Hepatol. 2019;18:434-8
Open access
Acute onset autoimmune hepatitis: Clinical presentation and treatment outcomes
Abdulrahman A. Aljumah, Hamad Al-Ashgar, Hind Fallatah, Ali Albenmousa
Ann Hepatol. 2019;18:439-44
Open access
Transient hepatic elastography has the best performance to evaluate liver fibrosis in non-alcoholic fatty liver disease (NAFLD)
Cristiane V. Tovo, Cristiane A. Villela-Nogueira, Nathalie C. Leite, Carine L. Panke, Gabriela Z. Port, Sabrina Fernandes, Caroline Buss, Gabriela P. Coral, ... Angelo A. de Mattos
Ann Hepatol. 2019;18:445-9
Open access
Sofosbuvir-based antiviral therapy in patients with recurrent HCV infection after liver transplant: A real-life experience
Alexandre Araujo, Vanessa Valenzuela-Granados, Antonio B. Lopes, Matheus T. Michalczuk, Augusto Mantovani, Mario R. Alvares-da-Silva
Ann Hepatol. 2019;18:450-5
Open access
Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China
Min Xu, Yiling Li, Shuang Zhang, Xinyi Wang, Jianhua Shen, Shuwen Zhang
Ann Hepatol. 2019;18:456-60
Open access
Insurance status impacts treatment for hepatocellular carcinoma
Lindsay A. Sobotka, Alice Hinton, Lanla F. Conteh
Ann Hepatol. 2019;18:461-5
Open access
Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population
Daniel F. Mazo, Fernanda M. Malta, Jose Tadeu Stefano, Ana Paula M. Salles, Michele S. Gomes-Gouvea, Ana Catharina S. Nastri, Jazon R. Almeida, Joao Renato R. Pinho, ... Claudia P. Oliveira
Ann Hepatol. 2019;18:466-71
Open access
An aqueous extract of Stevia rebaudiana variety Morita II prevents liver damage in a rat model of cirrhosis that mimics the human disease
Erika Ramos-Tovar, Rosa E. Flores-Beltrán, Silvia Galindo-Gómez, Javier Camacho, Víctor Tsutsumi, Pablo Muriel
Ann Hepatol. 2019;18:472-9
Open access
A different gut microbiome linked to inflammation found in cirrhotic patients with and without hepatocellular carcinoma
Federico Piñero, Martín Vazquez, Patricia Baré, Cristian Rohr, Manuel Mendizabal, Mariela Sciara, Cristina Alonso, Fabián Fay, Marcelo Silva
Ann Hepatol. 2019;18:480-7
Open access
Treatment response in primary biliary cholangitis: The role of autoimmune hepatitis features
Fernando Mané, Hélder Cardoso, Rodrigo Liberal, Susana Lopes, Pedro Pereira, Regina Gonçalves, Guilherme Macedo
Ann Hepatol. 2019;18:488-93
Open access
Pegylated interferon-α inhibits the proliferation of hepatocellular carcinoma cells by downregulating miR-155
Ying Zhang, Xuefeng Li, Yong Zhang, Lin Wang, Jiao Xu, Jinghua Du, Yonghai Guan
Ann Hepatol. 2019;18:494-500
Open access
Epidemiology of drug-induced liver injury in a University Hospital from Colombia: Updated RUCAM being used for prospective causality assessment
Alejandra Cano-Paniagua, Pedro Amariles, Nancy Angulo, Margarita Restrepo-Garay
Ann Hepatol. 2019;18:501-7
Open access
Case report
Transfer of peanut allergy from donor to recipient after liver transplant
Avin Aggarwal, Rilwan Balogun, Tara F. Carr, Archita P. Desai, Tun Jie, Jen-Jung Pan
Ann Hepatol. 2019;18:508-13
Open access
Acute liver injury, acute liver failure and acute on chronic liver failure: A clinical spectrum of poisoning due to Gyromitra esculenta
Magdalena Arłukowicz-Grabowska, Maciej Wójcicki, Joanna Raszeja-Wyszomirska, Monika Szydłowska-Jakimiuk, Bernard Piotuch, Piotr Milkiewicz
Ann Hepatol. 2019;18:514-6
Open access
News
Clinical practice guidelines
Alcohol-related liver disease: Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH)
Juan P. Arab, Juan P. Roblero, Jose Altamirano, Fernando Bessone, Roberta Chaves Araujo, Fatima Higuera-De la Tijera, Juan Carlos Restrepo, Aldo Torre, ... Ramon Bataller
Ann Hepatol. 2019;18:518-35
Open access
Publish in
Annals of Hepatology
Special content about COVID-19
- Outcomes and factors associated with relapse of vaccine-induced liver injury after SARS CoV-2 immunization: A nationwide study
- Matrix metalloproteinase-2 inducing COL1A1 synthesis via integrin alpha Ⅴ promotes invasion and metastasis of cholangiocarcinoma cells
- P-2 NASH IS IMPROVED THROUGH MODIFICATIONS IN H3K9 METHYLATION BY PIRFENIDONE ACTING AS JMJD2B DEMETHYLASE ANTAGONIST.
- O-2 EVALUATION OF RISK FACTORS AND PROGNOSIS OF HEPATOCELLULAR CARCINOMA RECURRENCE AFTER LIVER TRANSPLANTATION
Affiliated societies
